American Nimodipine Study "ANS"

Completed

Phase 3 Results

Trial Description

To test the hypothesis that nimodipine would reduce the frequency of death and of worsening by 30% compared with placebo.

Interventions

  • Nimodipine (NimotopĀ®)Drug
    Intervention Desc: Calcium channel blocker (L-type calcium channels)

Trial Design

Randomized, double-blind, multicenter clinical trial of 1,064 patients.

Patient Involvement

Nimodipine was used in doses of 60 mg, 120 mg, and 240 mg daily and patients were treated for 21 days.

Outcomes

Type Measure Time Frame Safety Issue
Primary The Toronto Scale and the motor strength scale from the NINDS Stroke Data Bank as measured at 4, 10 and 21 days. Also, mortality during first 21 days of treatment.

Sponsors

Miles Inc., Bayer AG, the Horace W. Goldsmith Foundation, and the Remin Fund